|
gptkbp:instanceOf
|
gene editing technology
|
|
gptkbp:advantage
|
high specificity
low off-target effects
|
|
gptkbp:alternativeTo
|
gptkb:CRISPR-Cas_systems
gptkb:ZFNs
meganucleases
|
|
gptkbp:application
|
genome editing
disease modeling
functional genomics
cell line engineering
crop improvement
gene knockout
gene correction
gene insertion
|
|
gptkbp:component
|
gptkb:TALE_DNA-binding_domain
FokI nuclease domain
|
|
gptkbp:contrastsWith
|
gptkb:CRISPR-Cas9
gptkb:ZFN_gene_editing
|
|
gptkbp:deliveredBy
|
viral vectors
mRNA injection
plasmid transfection
|
|
gptkbp:developedBy
|
gptkb:Joung_Lab
gptkb:Voytas_Lab
|
|
gptkbp:firstDescribed
|
2010
|
|
gptkbp:fullName
|
gptkb:Transcription_Activator-Like_Effector_Nuclease_gene_editing
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
TALEN gene editing
|
|
gptkbp:limitation
|
labor-intensive design
large protein size
|
|
gptkbp:mechanismOfAction
|
induces double-strand breaks in DNA
|
|
gptkbp:notablePublication
|
gptkb:Nature_2011,_Miller_et_al.
gptkb:Science_2010,_Christian_et_al.
|
|
gptkbp:patent
|
gptkb:Sangamo_BioSciences
|
|
gptkbp:regulates
|
subject to biosafety guidelines
subject to ethical review
|
|
gptkbp:relatedTo
|
gptkb:biotechnology
synthetic biology
genetic engineering
|
|
gptkbp:targetingMechanism
|
customizable DNA-binding domains
|
|
gptkbp:usedFor
|
gptkb:agricultural_machinery
basic research
therapeutic research
gene therapy (experimental)
|
|
gptkbp:usedIn
|
animals
plants
microorganisms
human cells
|
|
gptkbp:uses
|
engineered nucleases
|
|
gptkbp:bfsParent
|
gptkb:Cellectis
|
|
gptkbp:bfsLayer
|
7
|